Citigroup
BRTX icon

Citigroup’s BioRestorative Therapies BRTX Stock Holding History

Citigroup’s Portfolio BRTX Stock Details BRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24K Buy
+3,186
New +$18.6K ﹤0.01% 5128
2025
Q4 		– Hold
0
– -$1 – 6092
2025
Q3 		– Hold
0
– – – 6035

Other funds holding BRTX

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.2B AUM 26.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
KFGK
Keystone Financial Group (Kentucky) Lexington, Kentucky $1.69B AUM 40.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Citigroup's BRTX Position: Q2 2026 in Review

Citigroup opened a new position in BioRestorative Therapies (BRTX) in Q2 2026: 3,186 shares worth $24K. The stake represents ﹤0.01% of the portfolio and ranks #5128 among its holdings.

18 funds tracked by Wall St. Rank hold BRTX as of Q2 2026.

  • Citigroup held 3,186 shares of BioRestorative Therapies worth $24K as of Q2 2026.
  • BioRestorative Therapies was a new Citigroup position in Q2 2026.
  • BioRestorative Therapies made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #5128 holding.
  • 18 funds tracked by Wall St. Rank held BioRestorative Therapies as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.